LYPE:XETRA:XETRA-Lyxor MSCI World Health Care TR UCITS ETF - C-EUR EUR (EUR)

ETF | Others |

Last Closing

USD 495.9

Change

-0.35 (-0.07)%

Market Cap

USD 0.78B

Volume

469.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The Sub-Fund is an index-tracking UCITS passively managed. The Reference Currency of the Sub-Fund is the Euro (EUR). The investment objective of sub-fund is to track both the upward and the downward evolution of the MSCI World Health Care Index " Net Total Return (the Index) denominated in US Dollars - while minimising the volatility of the difference between the return of the Sub-Fund and the return of the Index (the "Tracking Error"). The anticipated level of the tracking error under normal market conditions is expected to be up to 0.50%.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.80 (-1.54%)

USD 426.26B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.33 (-1.97%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

-0.13 (-0.46%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.13 (-0.44%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.23 (-0.93%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

-0.23 (-0.49%)

USD 104.42B
8R80:XETRA Amundi Index Solutions - Amund..

-0.86 (-0.60%)

USD 104.42B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

-0.28 (-0.54%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

+0.39 (+0.37%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+2.70 (+0.45%)

USD 80.38B

ETFs Containing LYPE:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.31% 61% D- 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.31% 60% D- 61% D-
Trailing 12 Months  
Capital Gain 18.13% 64% D 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.13% 63% D 64% D
Trailing 5 Years  
Capital Gain 60.62% 79% B- 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 60.62% 77% C+ 76% C+
Average Annual (5 Year Horizon)  
Capital Gain 11.19% 73% C 71% C-
Dividend Return 11.19% 72% C 69% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 9.17% 65% D 72% C
Risk Adjusted Return 122.05% 100% F 99% N/A
Market Capitalization 0.78B 73% C 64% D

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike